Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Payables (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Payables for 14 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 60.11% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2025, down 60.11%, and an annual FY2025 reading of $1.9 million, down 75.66% over the prior year.
  • Payables was $1.9 million for Q4 2025 at Enanta Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Across five years, Payables topped out at $11.8 million in Q1 2023 and bottomed at $1.2 million in Q2 2022.
  • Average Payables over 5 years is $6.1 million, with a median of $5.9 million recorded in 2021.
  • The sharpest move saw Payables plummeted 78.88% in 2022, then surged 537.11% in 2023.
  • Year by year, Payables stood at $7.8 million in 2021, then tumbled by 44.5% to $4.4 million in 2022, then surged by 114.29% to $9.3 million in 2023, then plummeted by 49.32% to $4.7 million in 2024, then plummeted by 60.11% to $1.9 million in 2025.
  • Business Quant data shows Payables for ENTA at $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $3.5 million in Q2 2025.